Published in final edited form as:

Reprod Toxicol. 2014 August ; 47: 111–114. doi:10.1016/j.reprotox.2014.04.008.

Anticonvulsants Teratogenic Mechanism Involves Alteration of Bioelectrically-controlled Processes in the Embryo. A hypothesis

Sonia Hernández-Díaz, M.D., Dr.P.H.^{*1} and Michael Levin, Ph.D.²

¹Department of Epidemiology, Harvard School of Public Health, Boston, MA

²Department of Biology, and Center for Regenerative and Developmental Biology, Tufts University, Medford, MA

Abstract

Maternal use of anticonvulsants during the first trimester of pregnancy has been associated with an elevated risk of major congenital malformations in the offspring. Whether the increased risk is caused by the specific pharmacological mechanisms of certain anticonvulsants, the underlying epilepsy, or common genetic or environmental risk factors shared by epilepsy and malformations is controversial. We hypothesize that anticonvulsant therapies during pregnancy that attain more successful inhibition of neurotransmission might lead to both better seizure control in the mother and stronger alteration of bioelectrically-controlled processes in the embryo that result in structural malformations. If our theory were correct, development of pharmaceuticals that do not alter cell resting transmembrane voltage levels could result in safer drugs.

Mechanism of pharmacologic action of anticonvulsants

The aim of anticonvulsants is to suppress the excessive firing of neurons that start a seizure to prevent the spread of the seizure within the brain. Drugs exert their anticonvulsant action through enhancement of inhibitory neurotransmission or/and reduction of excitatory neurotransmission. The mechanism of anticonvulsant drug action is complex and remains uncertain. The main proposed mechanisms of action include: 1) Block of voltage-sensitive sodium (Na⁺) channels, which inhibits firing of action potentials by axons (e.g., phenytoin, carbamazepine, lamotrigine, valproate, topiramate, zonisamide). 2) Enhance the inhibitory neurotransmitter gamma-aminobutyric acid (GABA; e.g., benzodiazepines, gabapentin, valproate, phenobarbital). 3) Block the excitatory neurotransmitter glutamate (e.g. lamotrigine). 4) Blockage of the T type calcium channels (e.g. ethosuximide, pregabalin).

© 2014 Elsevier Inc. All rights reserved.

^{*}Author for correspondence.

Conflicts: Nothing to declare.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Anticonvulsants and major malformations in humans

Prenatal exposure to antiepileptic drugs (AEDs) has been associated with an increased risk of congenital malformations. However, the magnitude of the risks and the specific abnormalities vary for each drug.¹⁻³ In the North American AED Pregnancy Registry, the estimated risk of major malformations overall associated with first trimester exposure ranged from 9.3% for valproate to 2.0% for lamotrigine⁴. The risk of oral clefts was over 10 per 1,000 for infants exposed to phenobarbital, valproate or topiramate monotherapies, which is higher than expected based on any reference population (around 1 per 1,000)^{5,6}.

The teratogenicity of valproic acid has been established for three decades.⁷⁻⁹ It is widely accepted that first trimester exposure to valproic acid increases the risk of neural tube defects from around 1 to 10 per 1,000 births^{7,8,10-12}. Some studies have also suggested an association with hypospadias,⁸⁻¹² oral clefts,^{8,10,12} cardiac septal defects,⁹⁻¹² and limb defects.^{11,12} Other traditional AEDs may increase the risk of malformations two to three times: Primidone and its metabolite phenobarbital have been associated with oral clefts, cardiovascular and urogenital defects.¹³ Although less common, oral clefts, cardiovascular defects and urogenital defects have also been reported after phenytoin therapy.^{14,15} In utero exposure to carbamazepine has been associated with cleft palate,¹⁶ neural tube defects^{14,16,17} hypospadias and cardiovascular defects.¹⁶

The use of newer AEDs such as lamotrigine, topiramate and levetiracetam has increased in recent years. Studies consistently show a lower risk of malformations overall for lamotrigine than for the traditional AEDs.^{8,18-20} However, the risk of oral clefts reported for lamotrigine has ranged from 1.0 to 4.5 per 1,000,^{4,8,20,21} and whether lamotrigine increases the risk of oral clefts is still under discussion. For topiramate, at least four studies have already suggested an increased risk of oral clefts.^{22,23,24} There is a limited amount of information available for levetiracetam and other new generation AEDs.

In summary, most traditional and some new AEDs have been associated with relatively specific defects (i.e. oral clefts, neural tube defects, cardiac defects, and urogenital defects) to different degrees.

Role of epilepsy

Evaluation of the teratogenic effects of AEDs is complicated by the fact that epilepsy itself could potentially increase the risk of birth defects.^{25,26} However, the risk of malformations is higher in the offspring of women on AEDs than in those with untreated epilepsy during pregnancy,^{1,27,28} and women with a history of epilepsy but taking no AED do not have an increased risk of having children with major malformations.^{29,30} Although these observations might reflect an effect of disease severity, since epilepsy can seldom remain untreated and untreated women might not be comparable to women on AEDs, they are also compatible with AEDs effects. Moreover, the type of epilepsy and the number of seizures during pregnancy do not affect the risk of malformations.^{19,27,28,31,32} In addition, in recent years, several anticonvulsants have been increasingly used as mood stabilizers. Studies that looked at the prevalence of congenital anomalies according to indication (psychiatric vs.

neurologic) suggest that the teratogenic effect is probably a drug effect rather than the epilepsy.^{29,30}

Teratogenic mechanism

The mechanisms of teratogenicity of AEDs are largely unknown and may be different for different AEDs. One potential mechanism concerns folate. While it is widely accepted that several AEDs produce low folate levels,^{33,34} and that both low folate levels and AED use correlate with adverse pregnancy outcomes, it is unclear whether AED-induced low folate levels in the mother are themselves responsible for the higher risk of malformations.³⁵ Several alternative teratogenic mechanisms have been proposed,³⁶ including a direct effect on DNA synthesis of developing cells,^{27,37} valproate inhibition of cell differentiation and induction of apoptosis through oxidative stress caused by the formation of reactive oxygen species,³⁸ and valproate modification of gene expression through histone deacetylase inhibition.³⁹ Such a global effect on cell division would explain a broad spectrum of defects associated with prenatal AED exposure. However, AEDs have been associated with relatively specific defects (i.e. oral clefts, NTDs, cardiac defects, and urogenital defects). Intriguingly, all these malformations might be due to alterations in the fusion process of embryonic folds.

One likely mechanism mediating these effects concerns interference with the endogenous bioelectric mechanisms guiding embryonic development⁴⁰⁻⁴². In addition to action potentials in neurons, slowly-changing gradients of resting transmembrane voltage levels are present in all cells. It is now known that these voltage gradients function as instructive cues guiding cell division⁴³, programmed cell death⁴⁴, cell positioning and orientation^{45,46}, and differentiation⁴⁷⁻⁴⁹. More broadly, such bioelectric cues are an important mechanism for orchestrating individual cell behaviors into large-scale patterning programs, and have been implicated in craniofacial development^{50,51}, left-right patterning of the heart and viscera⁵²⁻⁵⁴, neoplastic transformation⁵⁵⁻⁵⁸, eye development⁵⁹, neuronal patterning^{60,61}, and other aspects of the control of biological growth and form^{62,63}. Any perturbation of ion channel function by pharmacological compounds is likely to disrupt the fine balance of resting potentials that provides positional information and other growth guidance to cells and tissues during embryogenesis,^{64,65} being especially relevant for actively-growing and stem cells⁶⁶⁻⁶⁸. Moreover, it has been shown that several neurotransmitters function as regulators of these gradients⁶⁹⁻⁷², as well as downstream players that transduce voltage changes into regulation of gene expression⁷³⁻⁷⁵. Thus, drugs that modulate serotonergic and GABA/glycine receptors or transporters may also impact on the developmental outcomes required for normal embryogenesis.

Effectiveness of specific anticonvulsants preventing seizures during pregnancy

In a recent study, AED groups associated with the lowest frequency of seizures in the mother, like valproate or phenobarbital, also carried the greatest risk of major malformations in the fetus⁴. Newer drugs, like lamotrigine, seem safer for the fetus but may be less effective to control seizures during pregnancy.⁷⁶ The differences in effectiveness observed

among the drugs in these non-randomized studies may be due to lack of comparability of treatment groups regarding the underlying indication. Clinicians might keep women of childbearing age on valproate or phenobarbital when they are well controlled and are reluctant to switch and risk seizure recurrence, while newer AEDs could have been prescribed to patients not responding to traditional drugs. In addition, reduced effectiveness in seizure control during pregnancy might be the result of increased clearance or other pharmacokinetic changes associated with gestation, which may be particularly pronounced for specific AEDs. Whatever the explanation might be, it is intriguing that less effective seizure control during pregnancy seemed safer for fetal development.

Hypothesis

Based on these observations, we hypothesize that more successful inhibition of neurotransmission might lead to both better seizure control in the mother and stronger alteration of bioelectrically-controlled processes in the embryo that result in structural malformations. This hypothesis is supported on the following premises: 1) Through different mechanisms, all AEDs affect neuronal transmission and voltage gradients in non-neuronal cells. 2) Bioelectrical gradients, as well as associated upstream and downstream neurotransmitter-regulated mechanisms, are crucial regulators of patterning in numerous developmental systems, controlling somatic and stem cell behavior, and thus regulating morphogenesis at the tissue and organ levels. 3) Thus, substances that affect neurotransmitters and ion channels could not only reduce neuronal transmission and prevent seizures but also impair developmental events such as axial patterning, visceral organ positioning, neural and vascular network specification, craniofacial morphogenesis, and limb and neural tube patterning.

Acknowledgments

ML gratefully acknowledges support of the NIH (grants EY018168, AR061988, and GM077425), American Heart Association (Established Investigator Grant 0740088N), and the G. Harold and Leila Y. Mathers Charitable Foundation. SHD gratefully acknowledges support of the Agency for Healthcare Research and Quality (AHRQ) (Grant R01HS018533).

References

1. Holmes LB, Harvey EA, Coull BA, et al. The teratogenicity of anticonvulsant drugs. *New England Journal of Medicine*. 2001; 344:1132–8. [PubMed: 11297704]
2. Matalon S, Schechtman S, Goldzweig G, Ornoy A. The teratogenic effect of carbamazepine: a meta-analysis of 1255 exposures. *Reproductive Toxicology*. 2002; 16:9–17. [PubMed: 11934528]
3. Wyszynski D, Nambisan M, Surve T, Alsdorf R, Smith C, Holmes L. Antiepileptic drug pregnancy registry: increased rate of major malformations in offspring exposed to valproate during pregnancy. *Neurology*. 2005; 64:956–61.
4. Hernandez-Diaz S, Smith CR, Shen A, et al. Comparative safety of antiepileptic drugs during pregnancy. *Neurology*. 2012; 78:1692–9. [PubMed: 22551726]
5. Nelson K, Holmes LB. Malformations due to presumed spontaneous mutations in newborn infants. *New England Journal of Medicine*. 1989; 320:19–23. [PubMed: 2909875]
6. Peller A, Westgate MN, Holmes L. Trends in congenital malformations, 1974-1999: effect of prenatal diagnosis and elective termination. *Obstetrics and gynecology*. 2004; 104:957–64. [PubMed: 15516385]

7. Omtzigt J, Los F, Grobbee D, et al. The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. *Neurology*. 1992; 42:119–25. [PubMed: 1574165]
8. Morrow J, Russell A, Guthrie B, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. *J Neurol Neurosurg Psychiatry*. 2006; 77:193–8. [PubMed: 16157661]
9. Diav-Citrin O, Shechtman S, Bar-Oz B, Cantrell D, Arnon J, Ornoy A. Pregnancy Outcome after In Utero Exposure to Valproate Evidence of Dose Relationship in Teratogenic Effect. *CNS drugs*. 2008; 22:325–34. [PubMed: 18336060]
10. Wide K, Winbladh B, Kallen B. Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. *Acta Paediatrica Scandinavica*. 2004; 93:174–6.
11. Arpino C, Brescianini S, Robert E, et al. Teratogenic Effects of Antiepileptic Drugs: Use of an International Database on Malformations and Drug Exposure (MADRE). *Epilepsia*. 2000; 41:1436–46. [PubMed: 11077457]
12. Jentink J, Loane M, Dolk H, et al. Valproic Acid Monotherapy in Pregnancy and Major Congenital Malformations. *New England Journal of Medicine*. 2010; 362:2185–93. [PubMed: 20558369]
13. Nakane Y, Okuma T, Takahashi R, et al. Multi-institutional study on the teratogenicity and fetal toxicity of antiepileptic drugs: A report of a collaborative study group in Japan. *Epilepsia*. 1980; 21:663–80. [PubMed: 7439133]
14. Czeizel AE, Bod M, Halasz P. Evaluation of anticonvulsant drugs during pregnancy in a population-based Hungarian study. *European journal of epidemiology*. 1992; 8:122–7. [PubMed: 1572421]
15. Dansky LV, Rosenblatt DS, Andermann E. Mechanisms of teratogenesis: Folic acid and antiepileptic therapy. *Neurology*. 1992; 42:32–42. [PubMed: 1574174]
16. Jentink J, Dolk H, Loane M, et al. Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and casecontrol study. *British medical journal*. 2010; 341
17. Kallen BA. Maternal carbamazepine and infant spina bifida. *Reproductive Toxicology*. 1994; 8:203–5. [PubMed: 8075508]
18. Sabers A, Dam M, a-Rogvi-Hansen B, et al. Epilepsy and pregnancy: lamotrigine as main drug used. *Acta Neurologica Scandinavica*. 2004; 109:9–13. [PubMed: 14653845]
19. Vajda F, Hitchcock A, Graham J, O'Brien T, Lander C, Eadie M. The Australian Register of Antiepileptic Drugs in Pregnancy: The first 1002 pregnancies. *Australian & New Zealand Journal of Obstetrics & Gynaecology*. 2007; 47:468–74. [PubMed: 17991111]
20. Cunnington M, Ferber S, Quartey G, International Lamotrigine Pregnancy Registry Scientific Advisory Committee. Effect of Dose on the Frequency of Major Birth Defects Following Fetal Exposure to Lamotrigine Monotherapy in an International Observational Study. *Epilepsia*. 2007; 48:1207–10. [PubMed: 17381445]
21. Holmes LB, Baldwin E, Habecker E, Glassman L, Wong S, Wyszynsky DF. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. *Neurology*. 2008; 70:2152–58. [PubMed: 18448870]
22. Hunt S, Russell A, Smithson W, et al. Topiramate in pregnancy. Preliminary experience from the UK Epilepsy and Pregnancy Register. *Neurology*. 2008; 71:272–6. [PubMed: 18645165]
23. Molgaard-Nielsen D, Hviid A. Newer-generation antiepileptic drugs and the risk of major birth defects. *JAMA : the journal of the American Medical Association*. 2011; 305:1996–2002. [PubMed: 21586715]
24. Margulis AV, Mitchell AA, Gilboa SM, et al. Use of topiramate in pregnancy and risk of oral clefts. *American journal of obstetrics and gynecology*. 2012; 207:405, e1–7. [PubMed: 22917484]
25. Shapiro S, Hartz SC, Siskind V, et al. Anticonvulsants and parental epilepsy in the development of birth defects. *Lancet*. 1976; 1:272–5. [PubMed: 55587]
26. Gadoth N, Millo Y, Taube E, Bechar M. Epilepsy among parents of children with cleft lip and palate. *Brain & development*. 1987; 9:296–9. [PubMed: 3661909]
27. Finnell, RH.; Bielec, B.; Nau, H. Anticonvulsant drugs: Mechanisms and pathogenesis of teratogenicity. In: Kavlock, RJ.; Daston, GP., editors. *Drug Toxicity in embryonic development II*. Berlin: Springer; 1997. p. 121–59.

28. Dansky LV, Finnell RH. Parental epilepsy, anticonvulsant drugs, and reproductive outcome: Epidemiologic and experimental findings spanning three decades; 2: Human studies. *Reproductive Toxicology*. 1991; 5:301–35. [PubMed: 1806139]
29. Fried S, Kozer E, Nulman I, Einarson TR, Koren G. Malformation rates in children of women with untreated epilepsy: a meta-analysis. *Drug Safety*. 2004; 27:197–202. [PubMed: 14756581]
30. Werler MM, Ahrens KA, Bosco JL, et al. Use of antiepileptic medications in pregnancy in relation to risks of birth defects. *Annals of epidemiology*. 2011; 21:842–50. [PubMed: 21982488]
31. Kaneko S, Battino D, Andermann E, et al. Congenital malformations due to anti-epileptic drugs. *Epilepsy research*. 1999; 33:145–58. [PubMed: 10094426]
32. Bromfield E, Dworetzky B, Wyszynski D, Smith C, Baldwin E, Holmes L. Valproate teratogenicity and epilepsy syndrome. *Epilepsia*. 2008; 49:2122–4. [PubMed: 18557775]
33. Butterworth C, Tamura T. Folic acid safety and toxicity: a brief review. *American Journal of Clinical Nutrition*. 1989; 50:353–8. [PubMed: 2667316]
34. Ogawa Y, Kaneko S, Otani K, Fukushima Y. Serum folic acid levels in epileptic mothers and their relationship to congenital malformations. *Epilepsy research*. 1991; 8:75–8. [PubMed: 2060505]
35. Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. *The New England journal of medicine*. 2000; 343:1608–14. [PubMed: 11096168]
36. Buehler BA, Delimont D, Van Waes M, Finnell RH. Prenatal prediction of risk of the fetal hydantoin syndrome. *New England Journal of Medicine*. 1990; 322:1567–72. [PubMed: 2336087]
37. Lindhout D. Pharmacogenetics and drug interactions; Role in antiepileptic-drug-induced teratogenesis. *Neurology*. 1992; 42:43–7. [PubMed: 1574175]
38. Na L, Wartenberg M, Nau H, Hescheler J, Sauer H. Anticonvulsant valproic acid inhibits cardiomyocyte differentiation of embryonic stem cells by increasing intracellular levels of reactive oxygen species. *Birth defects research Part A, Clinical and molecular teratology*. 2003; 67:174–80.
39. Wu G, Nan C, Rollo JC, Huang X, Tian J. Sodium valproate-induced congenital cardiac abnormalities in mice are associated with the inhibition of histone deacetylase. *Journal of biomedical science*. 2010; 17:16. [PubMed: 20219112]
40. Levin M. Molecular bioelectricity in developmental biology: New tools and recent discoveries: Control of cell behavior and pattern formation by transmembrane potential gradients. *Bioessays*. 2012
41. Levin M. Bioelectric mechanisms in regeneration: Unique aspects and future perspectives. *Seminars in Cell & Developmental Biology*. 2009; 20:543–56. [PubMed: 19406249]
42. McCaig CD, Song B, Rajnicek AM. Electrical dimensions in cell science. *J Cell Sci*. 2009; 122:4267–76. [PubMed: 19923270]
43. Blackiston DJ, McLaughlin KA, Levin M. Bioelectric controls of cell proliferation: ion channels, membrane voltage and the cell cycle. *Cell Cycle*. 2009; 8:3519–28.
44. Burg ED, Remillard CV, Yuan JX. K⁺ channels in apoptosis. *J Membr Biol*. 2006; 209:3–20. [PubMed: 16685597]
45. Rajnicek AM, Foubister LE, McCaig CD. Growth cone steering by a physiological electric field requires dynamic microtubules, microfilaments and Rac-mediated filopodial asymmetry. *J Cell Sci*. 2006; 119:1736–45. [PubMed: 16595545]
46. McCaig CD, Rajnicek AM, Song B, Zhao M. Controlling cell behavior electrically: current views and future potential. *Physiol Rev*. 2005; 85:943–78. [PubMed: 15987799]
47. Hinard V, Belin D, Konig S, Bader CR, Bernheim L. Initiation of human myoblast differentiation via dephosphorylation of Kir2.1 K⁺ channels at tyrosine 242. *Development*. 2008; 135:859–67. [PubMed: 18216177]
48. Konig S, Beguet A, Bader CR, Bernheim L. The calcineurin pathway links hyperpolarization (Kir2.1)-induced Ca²⁺ signals to human myoblast differentiation and fusion. *Development*. 2006; 133:3107–14. [PubMed: 16831831]
49. Konig S, Hinard V, Arnaudeau S, et al. Membrane hyperpolarization triggers myogenin and myocyte enhancer factor-2 expression during human myoblast differentiation. *J Biol Chem*. 2004; 279:28187–96. [PubMed: 15084602]

50. Vandenberg LN, Morrie RD, Adams DS. V-ATPase-dependent ectodermal voltage and pH regionalization are required for craniofacial morphogenesis. *Dev Dyn*. 2011; 240:1889–904. [PubMed: 21761475]
51. Tristani-Firouzi M, Etheridge SP. Kir 2.1 channelopathies: the Andersen-Tawil syndrome. *Pflugers Arch*. 2010; 460:289–94. [PubMed: 20306271]
52. Adams DS, Robinson KR, Fukumoto T, et al. Early, H⁺-V-ATPase-dependent proton flux is necessary for consistent left-right patterning of non-mammalian vertebrates. *Development*. 2006; 133:1657–71. [PubMed: 16554361]
53. Levin M, Thorlin T, Robinson KR, Nogi T, Mercola M. Asymmetries in H⁺/K⁺-ATPase and cell membrane potentials comprise a very early step in left-right patterning. *Cell*. 2002; 111:77–89. [PubMed: 12372302]
54. Aw S, Koster J, Pearson W, et al. The ATP-sensitive K(+) -channel (K(ATP)) controls early left-right patterning in *Xenopus* and chick embryos. *Dev Biol*. 2010; 346:39–53. [PubMed: 20643119]
55. Blackiston D, Adams DS, Lemire JM, Lobikin M, Levin M. Transmembrane potential of GlyCl-expressing instructor cells induces a neoplastic-like conversion of melanocytes via a serotonergic pathway. *Dis Model Mech*. 2011; 4:67–85. [PubMed: 20959630]
56. Ding Y, Brackenbury WJ, Onganer PU, et al. Epidermal growth factor upregulates motility of Mat-LyLu rat prostate cancer cells partially via voltage-gated Na⁺ channel activity. *J Cell Physiol*. 2008; 215:77–81. [PubMed: 17960590]
57. Brackenbury WJ, Djamgoz MB, Isom LL. An emerging role for voltage-gated Na⁺ channels in cellular migration: regulation of central nervous system development and potentiation of invasive cancers. *Neuroscientist*. 2008; 14:571–83. [PubMed: 18940784]
58. Fraser SP, Diss JK, Chioni AM, et al. Voltage-gated sodium channel expression and potentiation of human breast cancer metastasis. *Clin Cancer Res*. 2005; 11:5381–9. [PubMed: 16061851]
59. Pai VP, Aw S, Shomrat T, Lemire JM, Levin M. Transmembrane voltage potential controls embryonic eye patterning in *Xenopus laevis*. *Development*. 2012; 139:313–23. [PubMed: 22159581]
60. Fein AJ, Wright MA, Slat EA, Ribera AB, Isom LL. *scn1bb*, a zebrafish ortholog of SCN1B expressed in excitable and nonexcitable cells, affects motor neuron axon morphology and touch sensitivity. *J Neurosci*. 2008; 28:12510–22. [PubMed: 19020043]
61. Pineda RH, Svoboda KR, Wright MA, et al. Knockdown of Nav1.6a Na⁺ channels affects zebrafish motoneuron development. *Development*. 2006; 133:3827–36. [PubMed: 16943272]
62. Levin, M. Endogenous Bioelectric Signals as Morphogenetic Controls of Development, Regeneration, and Neoplasia. In: Pullar, CE., editor. *The Physiology of Bioelectricity in Development, Tissue Regeneration, and Cancer*. Boca Raton, FL: CRC Press; 2011. p. 39–89.
63. Beane WS, Morokuma J, Adams DS, Levin M. A Chemical Genetics Approach Reveals H₂K-ATPase-Mediated Membrane Voltage Is Required for Planarian Head Regeneration. *Chemistry & biology*. 2011; 18:77–89. [PubMed: 21276941]
64. Chen EH, Olson EN. Unveiling the Mechanisms of Cell-Cell Fusion. *Science*. 2005; 308:269–373.
65. Buznikov GA, Schmukler YB. Possible role of “prenervous” neurotransmitters in cellular interactions of early embryogenesis: A hypothesis. *Neurochemical Research*. 1981; 6:55–68. [PubMed: 6111760]
66. Lange C, Prenninger S, Knuckles P, Taylor V, Levin M, Calegari F. The H⁺ Vacuolar ATPase Maintains Neural Stem Cells in the Developing Mouse Cortex. *Stem Cells Dev*. 2011
67. Sundelacruz S, Levin M, Kaplan DL. Membrane potential controls adipogenic and osteogenic differentiation of mesenchymal stem cells. *PLoS ONE*. 2008; 3:e3737. [PubMed: 19011685]
68. Yasuda T, Adams DJ. Physiological roles of ion channels in adult neural stem cells and their progeny. *J Neurochem*. 2010; 114:946–59. [PubMed: 20492359]
69. Root CM, Velazquez-Ulloa NA, Monsalve GC, Minakova E, Spitzer NC. Embryonically expressed GABA and glutamate drive electrical activity regulating neurotransmitter specification. *J Neurosci*. 2008; 28:4777–84. [PubMed: 18448654]
70. Andang M, Hjerling-Leffler J, Moliner A, et al. Histone H2AX-dependent GABA(A) receptor regulation of stem cell proliferation. *Nature*. 2008; 451:460–4. [PubMed: 18185516]

71. Deisseroth K, Malenka RC. GABA excitation in the adult brain: a mechanism for excitation-neurogenesis coupling. *Neuron*. 2005; 47:775–7. [PubMed: 16157270]
72. Deisseroth K, Singla S, Toda H, Monje M, Palmer TD, Malenka RC. Excitation-neurogenesis coupling in adult neural stem/progenitor cells. *Neuron*. 2004; 42:535–52. [PubMed: 15157417]
73. Fukumoto T, Blakely R, Levin M. Serotonin transporter function is an early step in left-right patterning in chick and frog embryos. *Dev Neurosci*. 2005; 27:349–63. [PubMed: 16280633]
74. Fukumoto T, Kema IP, Levin M. Serotonin signaling is a very early step in patterning of the left-right axis in chick and frog embryos. *Curr Biol*. 2005; 15:794–803. [PubMed: 15886096]
75. Carneiro K, Donnet C, Rejtar T, et al. Histone Deacetylase activity is necessary for left-right patterning during vertebrate development. *BMC Dev Biol*. 2011; 11:29. [PubMed: 21599922]
76. Vajda F, Lander C, O'Brien T, et al. Australian Pregnancy Registry of Women Taking Antiepileptic Drugs. *Epilepsia*. 2004; 45:1466. [PubMed: 15509252]